Vera Therapeutics, Inc. (VERA) discloses CRO Nancy Boman as reporting insider

Q: What does Vera Therapeutics (VERA) disclose in Nancy Lee Boman’s Form 3?

Vera Therapeutics reports an initial Form 3 for Chief Regulatory Officer Nancy Lee Boman . It lists her as an officer insider, shows no reported transactions or derivative positions, and references Exhibit 24 as a Power of Attorney authorizing the filing.

Q: Does the Form 3 show that Nancy Lee Boman holds Vera Therapeutics (VERA) securities?

The Form 3 for Nancy Lee Boman does not list any specific holdings or derivative positions. Structured data indicate zero holding entries and no transactions, meaning no securities positions are reported in this initial ownership statement.

Q: What is Nancy Lee Boman’s role at Vera Therapeutics (VERA) in this insider report?

Nancy Lee Boman is identified as Chief Regulatory Officer of Vera Therapeutics. This officer status makes her a reporting insider for SEC purposes, requiring disclosure of her beneficial ownership on Form 3 even though no transactions or derivative positions are reported.

Q: What is the Exhibit 24 Power of Attorney mentioned in Vera Therapeutics (VERA) Form 3?

Exhibit 24 is identified as a Power of Attorney related to Nancy Lee Boman’s Form 3. It authorizes designated individuals to sign and submit SEC ownership reports on her behalf, streamlining compliance with insider reporting requirements for Vera Therapeutics.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Vera Therapeutics, Inc. has filed an initial statement of beneficial ownership on Form 3 for Nancy Lee Boman, who serves as Chief Regulatory Officer. The filing does not report any transactions or derivative positions and references Exhibit 24 as a Power of Attorney authorizing the filing.

Key Figures

Reported buy transactions: 0 Reported sell transactions: 0 Derivative positions reported: 0

3 metrics

Reported buy transactions 0 Initial beneficial ownership statement for Chief Regulatory Officer Nancy Lee Boman

Reported sell transactions 0 No sale transactions listed in the Form 3 data

Derivative positions reported 0 Derivative summary contains no reported options or similar instruments

Key Terms

Power of Attorney, Chief Regulatory Officer, reporting person

3 terms

Power of Attorney regulatory

"Remarks reference Exhibit 24 - Power of Attorney"

A power of attorney is a legal document that allows one person to make decisions and act on behalf of another person, often in financial or legal matters. It’s like giving someone a trusted helper or agent the authority to handle important tasks if you are unable to do so yourself. This matters to investors because it can impact how their assets are managed or transferred if they become unable to oversee their affairs.

Chief Regulatory Officer regulatory

"Officer title is listed as Chief Regulatory Officer"

reporting person regulatory

"Reporting person identified as Boman Nancy Lee"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Understanding Insider Trading Forms →

Available on EDGAR 08/05/2026 - 04:13 PM Accepted by SEC EDGAR 08/05/2026 - 04:12 PM

FAQ

What does Vera Therapeutics (VERA) disclose in Nancy Lee Boman’s Form 3?

Vera Therapeutics reports an initial Form 3 for Chief Regulatory Officer Nancy Lee Boman. It lists her as an officer insider, shows no reported transactions or derivative positions, and references Exhibit 24 as a Power of Attorney authorizing the filing.

Does the Form 3 show that Nancy Lee Boman holds Vera Therapeutics (VERA) securities?

The Form 3 for Nancy Lee Boman does not list any specific holdings or derivative positions. Structured data indicate zero holding entries and no transactions, meaning no securities positions are reported in this initial ownership statement.

What is Nancy Lee Boman’s role at Vera Therapeutics (VERA) in this insider report?

Nancy Lee Boman is identified as Chief Regulatory Officer of Vera Therapeutics. This officer status makes her a reporting insider for SEC purposes, requiring disclosure of her beneficial ownership on Form 3 even though no transactions or derivative positions are reported.

Are any trading plan transactions reported for Vera Therapeutics (VERA) in this Form 3?

No trading plan transactions are reported for Vera Therapeutics in this Form 3. The structured data show zero transactions across buy, sell, and derivative categories, and the Rule 10b5-1 plan status field is not marked as affirmatively used.

What is the Exhibit 24 Power of Attorney mentioned in Vera Therapeutics (VERA) Form 3?

Exhibit 24 is identified as a Power of Attorney related to Nancy Lee Boman’s Form 3. It authorizes designated individuals to sign and submit SEC ownership reports on her behalf, streamlining compliance with insider reporting requirements for Vera Therapeutics.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Boman Nancy Lee

(Last)

(First)

(Middle)

C/O VERA THERAPEUTICS, INC.

2000 SIERRA POINT PARKWAY, SUITE 1200

(Street)

BRISBANE

CALIFORNIA

94005

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
08/03/2026

3. Issuer Name and Ticker or Trading Symbol
Vera Therapeutics, Inc. [ VERA ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Regulatory Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)

Explanation of Responses:

Remarks:

Exhibit 24 - Power of Attorney

No securities are beneficially owned.

	/s/ Joseph R. Young, Attorney-in-Fact	08/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

Source: View Original Filing on SEC EDGAR